|
| 37672053 | Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes. | Eur Radiol | 2024 |
| 37672053 | Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes. | Eur Radiol | 2024 |
| 37658995 | Molecular neuropathology: an essential and evolving toolbox for the diagnosis and clinical management of central nervous system tumors. | Virchows Arch | 2024 |
| 38079455 | Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial. | Neuro Oncol | 2024 |
| 37875569 | Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2024 |
| 38079455 | Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial. | Neuro Oncol | 2024 |
| 37658995 | Molecular neuropathology: an essential and evolving toolbox for the diagnosis and clinical management of central nervous system tumors. | Virchows Arch | 2024 |
| 37875569 | Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2024 |
| 35976058 | Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas. | Neuro Oncol | 2023 |
| 35976058 | Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas. | Neuro Oncol | 2023 |
| 36227281 | Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. | Neuro Oncol | 2023 |
| 35882450 | The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. | Neuro Oncol | 2023 |
| 36437415 | Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. | Acta Neuropathol | 2023 |
| 36377252 | Clinical implementation of integrated molecular-morphologic risk prediction for meningioma. | Brain Pathol | 2023 |
| 35977048 | BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. | Neuro Oncol | 2023 |
| 37855895 | Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042. | Acta Neuropathol | 2023 |
| 37853454 | INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas. | Neurol Res Pract | 2023 |
| 37605249 | Diagnostic accuracy of a minimal immunohistochemical panel in at/rt molecular subtyping, correlated to dna-methylation profiling. | Acta Neuropathol Commun | 2023 |
| 37944590 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Nat Med | 2023 |
| 38026572 | Reference on copy number variations in pleomorphic xanthoastrocytoma: Implications for diagnostic approach. | Free Neuropathol | 2023 |
| 37735561 | A H3K27M-targeted vaccine in adults with diffuse midline glioma. | Nat Med | 2023 |
| 37733309 | Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations. | N Engl J Med | 2023 |
| 37999877 | Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow. | J Neurooncol | 2023 |
| 37643378 | Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600-Mutant Pediatric High-Grade Glioma. | J Clin Oncol | 2023 |
| 37715567 | The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 3-Summary of Imaging Findings on Glioneuronal and Neuronal Tumors. | J Magn Reson Imaging | 2023 |
| 37875973 | Refinement of diagnostic criteria for pediatric-type diffuse high-grade glioma, IDH- and H3-wildtype, MYCN-subtype including histopathology, TP53, MYCN and ID2 status. | Acta Neuropathol Commun | 2023 |
| 37553446 | The molecular diagnostic yield of frame-based stereotactic biopsies in the age of precision neuro-oncology: a cross-sectional study. | Acta Neurochir (Wien) | 2023 |
| 37870637 | PLAG1 fusions extend the spectrum of PLAG(L)-altered CNS tumors. | Acta Neuropathol | 2023 |
| 37776353 | Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics. | Acta Neuropathol | 2023 |
| 37287580 | Pediatric meningiomas: A literature review and diagnostic update. | Neurooncol Adv | 2023 |
| 37093271 | Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes. | Acta Neuropathol | 2023 |
| 36517594 | Autonomous rhythmic activity in glioma networks drives brain tumour growth. | Nature | 2023 |
| 36968291 | Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma. | Neurooncol Adv | 2023 |
| 36715306 | Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups. | Neuro Oncol | 2023 |
| 37279174 | Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. | Neuro Oncol | 2023 |
| 36966138 | Genomic characterization of DICER1-associated neoplasms uncovers molecular classes. | Nat Commun | 2023 |
| 36964296 | Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. | NPJ Precis Oncol | 2023 |
| 36959034 | Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. | Eur J Cancer | 2023 |
| 37075810 | LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. | Neuro Oncol | 2023 |
| 36702828 | Author Correction: Federated learning enables big data for rare cancer boundary detection. | Nat Commun | 2023 |
| 36635768 | Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. | Acta Neuropathol Commun | 2023 |
| 37069792 | The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1-Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas. | J Magn Reson Imaging | 2023 |
| 37069764 | The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2-Summary of Imaging Findings on Pediatric-Type Diffuse High-Grade Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Circumscribed Astrocytic Gliomas. | J Magn Reson Imaging | 2023 |
| 36632791 | EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. | Neuro Oncol | 2023 |
| 36871657 | Cerebellar Mutism Syndrome After Posterior Fossa Tumor Surgery in Children-A Retrospective Single-Center Study. | World Neurosurg | 2023 |
| 37188167 | Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling. | Neurooncol Pract | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 36798537 | Endothelial Indoleamine-2,3-Dioxygenase-1 is not Critically Involved in Regulating Antitumor Immunity in the Central Nervous System. | Int J Tryptophan Res | 2023 |
| 36993741 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Res Sq | 2023 |
| 36933012 | Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions. | Acta Neuropathol | 2023 |